Sold as Disipal. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Orphenadrine Hydrochloride (sold as Disipal), first approved May 10, 1957, with 0 new uses approved and 0 published complete response letters.
| Effectiveness of Chlorzoxazone Versus Orphenadrine Citrate in Alleviating Bruxism PainOrofacial Pain, Bruxism · University of Baghdad | Phase 4 | Recruiting | Aug 7, 2025 |
| Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With CirrhosisLiver Cirrhosis, Muscle Cramps · Sherief Abd-Elsalam | Phase 3 | Recruiting | Apr 22, 2015 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA